發(fā)布時間：2019-04-15 18:29

【摘要】：目的通過研究肝細胞肝癌中CD151及整合素α3、整合素β1的表達,探討它們與肝細胞肝癌的發(fā)生、發(fā)展的關系,并分析預后,為肝細胞肝癌的診治及臨床基礎研究提供新的診療思路。方法收集鄭州大學第一附屬醫(yī)院行肝細胞肝癌切除患者的臨床資料及石蠟標本組織52例。收集正常肝臟標本組織10例。采用免疫組化方法,檢測肝癌、癌旁組織及正常肝臟組織中CD151、整合素α3、整合素β1的表達情況及其相關性,同時分析肝癌患者的首次復發(fā)時間。分析這三種蛋白的表達情況與臨床病理特征的關系,以及與患者預后的相關性。結果1.CD151在肝癌組織中陽性表達率為70.3%,癌旁組織、正常肝臟組織中的表達分別為57.9%、21.4%(p0.05)。整合素α3在肝癌組織表達率為75.2%;癌旁組織、正常肝臟組織中的表達分別為56.7%、27.8%(p0.05)。整合素β1在肝癌組織表達陽性率為78.8%;癌旁組織、正常肝臟組織中的表達分別為62.4%、39.0%(p0.05)。2.CD151、整合素α3、整合素β1在肝癌中的表達呈正相關。CD151與整合素α3的spearman相關系數(shù)r=0.152,CD151與整合素β1的spearman相關系數(shù)r=0.081,整合素α3與整合素β1的spearman相關系數(shù)r=0.066,表達成正相關(p0.05)。3.CD151與整合素α3、整合素β1在低分化肝癌組織的陽性表達率較高-中分化肝癌組織陽性率高。CD151、整合素α3、整合素β1蛋白與肝癌分化程度的χ2分別是:7.140、11.244、5.223,差異具有統(tǒng)計學意義(p0.05)。4.CD151、整合素α3、整合素β1在肝癌中的表達率高,患者復發(fā)周期短。結論1.CD151與整合素α3、整合素β1在肝癌組織高表達,肝癌組織分化越低,蛋白表達陽性率越高。2.CD151、整合素α3、整合素β1蛋白的高表達可能影響患者的預后。
[Abstract]:Objective to study the expression of CD151, integrin 偽 3 and integrin 尾 1 in hepatocellular carcinoma (HCC), and to explore the relationship between them and the occurrence and development of HCC, and to analyze the prognosis of HCC. It provides a new way of diagnosis and treatment for hepatocellular carcinoma (HCC). Methods the clinical data and paraffin-embedded tissues of 52 cases of hepatocellular carcinoma (HCC) resected in the first affiliated Hospital of Zhengzhou University were collected. 10 normal liver tissues were collected. The expression of CD151, integrin 偽 3 and integrin 尾 1 in hepatocellular carcinoma (HCC), paracancerous tissues and normal liver tissues and their correlation were detected by immunohistochemical method. The first recurrence time of HCC patients was analyzed at the same time. To analyze the relationship between the expression of these three proteins and clinicopathological features, and to analyze the correlation between the expression of these three proteins and the prognosis of the patients. Results the positive expression rate of 1.CD151 was 70.3% in HCC tissues, 57.9% in paracancerous tissues and 21.4% in normal liver tissues (p0.05). The expression rate of integrin 偽 3 was 75.2% in HCC tissues and 56.7% and 27.8% in normal liver tissues, respectively (p0.05). The positive rate of integrin 尾 1 expression in HCC tissues was 78.8%. The expression of CD151, integrin 偽 3 and integrin 尾 1 was positively correlated with the expression of integrin 偽 3 and integrin 尾 1 in hepatocellular carcinoma. The spearman correlation coefficient between CD151 and integrin 偽 3 was 0.152, and the correlation coefficient between CD151 and integrin 偽 3 was 0.152, and the expression of integrin 偽 3 and integrin 尾 1 in normal liver tissues were 62.4%, 39.0% (p0.05). The correlation coefficient of spearman between CD151 and integrin 尾 1 was r = 0.081, and the correlation coefficient between integrin 偽 3 and integrin 尾 1 was r = 0.066, which was positively correlated with the expression of integrin 偽 3 (p0.05) .3.CD151 was positively correlated with integrin 偽 3, and integrin 偽 3 was positively correlated with integrin 偽 3. CD151, integrin 偽 3, integrin 尾 1 protein and differentiation degree of HCC were 7.140, 11.244,5.223,7.140, 11.244,5.223,respectively, the positive rates of integrin 尾 1 in poorly differentiated HCC tissues were higher than those in low differentiated HCC tissues, CD151, integrin 偽 3 and integrin 尾 1 protein were 7.140, 11.244,5.223,respectively. The expression rate of CD151, integrin 偽 3 and integrin 尾 1 in HCC was high, and the recurrence cycle was short. Conclusion the high expression of 1.CD151 and integrin 偽 3, integrin 尾 1 in HCC tissues, the lower the differentiation of HCC tissues, the higher the positive rate of protein expression. 2.CD151, integrin 偽 3 and integrin 尾 1 protein expression may affect the prognosis of patients.
【學位授予單位】：鄭州大學
【學位級別】：碩士
【學位授予年份】：2015
【分類號】：R735.7

【相似文獻】

相關期刊論文 前10條

1 朱立新,耿小平;肝細胞肝癌術后復發(fā)的危險因素、預防及治療[J];肝膽外科雜志;2000年06期

2 季偉,王慧芬;乙型肝炎病毒感染合并肝細胞肝癌153例臨床分析[J];中華肝臟病雜志;2001年06期

3 陳孝平;張志偉;楊甲梅;沈鋒;;肝細胞肝癌外科治療方法的選擇[J];中華普通外科學文獻(電子版);2008年06期

4 董碩;謝廣茹;吳雄志;;男性肝細胞肝癌術后預后因素分析[J];中國腫瘤臨床;2008年08期

5 陳孝平;張志偉;楊甲梅;沈鋒;;肝細胞肝癌外科治療方法的選擇[J];中華普通外科學文獻(電子版);2009年02期

6 郭洪生;杜智;高英堂;薛春祥;張勤;朱爭艷;王偉麗;;磷脂酰肌醇蛋白聚糖3在肝細胞肝癌中的表達及意義[J];中國腫瘤臨床;2009年08期

7 陳孝平;張志偉;楊甲梅;沈鋒;;肝細胞肝癌外科治療方法的選擇[J];中華普通外科學文獻(電子版);2010年01期

8 徐霽;;多齒針大劑量乙醇消融治療直徑5.0cm以內(nèi)的肝細胞肝癌[J];國際醫(yī)學放射學雜志;2010年01期

9 張國強;楊定華;李相z，

本文編號：2458374